Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
艾利布林联合依维莫司治疗转移性三阴性乳腺癌的Ⅰ期临床研究
作者: Jin Sun LeeSusan E. YostSuzette BlanchardDaniel SchmolzeHongwei Holly YinRaju PillaiKim RobinsonAileen TangNorma MartinezJana PortnowWei WenJohn H. YimHeather Ann BrauerYuqi RenThehang LuuJoanne MortimerYuan Yuan
作者单位: 1Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center and Beckman Research Institute, 1500 E. Duarte Road, 91010, Duarte, CA, USA
2Department of Biostatistics, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA
3Department of Pathology, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA
4Department of Surgery, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA
5NanoString Technologies, Inc., Seattle, WA, USA
6OncoGambit, Irvine, CA, USA
刊名: Breast Cancer Research, 2019, Vol.21 (9), pp.2492-2502
来源数据库: Springer Nature Journal
DOI: 10.1186/s13058-019-1202-4
关键词: Phase I trialEribulinEverolimusMetastatic TNBC
英文摘要: Abstract(#br)Background(#br)Alteration of the PI3K/AKT/mTOR pathway is a common genomic abnormality detected in triple-negative breast cancer (TNBC). Everolimus acts synergistically with eribulin in TNBC cell lines and xenograft models. This phase I trial was designed to test the safety and tolerability of combining eribulin and everolimus in patients with metastatic TNBC. Methods(#br)The primary objective of this study was to evaluate the safety and toxicities of the combination. Patients with metastatic TNBC who had up to four lines of prior chemotherapies were enrolled. The combination of eribulin and everolimus was tested using three dosing levels: A1 (everolimus 5 mg daily; eribulin 1.4 mg/m2 days 1 and 8 every 3 weeks), A2 (everolimus 7.5 mg daily; eribulin 1.4...
全文获取路径: Springer Nature  (合作)
分享到:
来源刊物:
影响因子:5.872 (2012)

×